AvalehtNVS • NYSE
add
Novartis AG
Viimane sulgemishind
104,87 $
Tänane vahemik
104,86 $ - 105,97 $
Aasta vahemik
92,35 $ - 120,92 $
Turuväärtus
233,63 mld USD
Keskmine maht
1,28 mln
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Käive | 13,17 mld | 8,93% |
Põhitegevusega seonduv kulu | 5,52 mld | −24,45% |
Puhastulu | 3,19 mld | 81,09% |
Puhaskasumimarginaal | 24,21 | 66,28% |
Puhaskasum aktsia kohta | 2,06 | 18,39% |
EBITDA | 5,50 mld | 88,62% |
Tõhus maksumäär | 5,91% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 13,85 mld | 8,08% |
Kogu vara | 103,52 mld | −8,14% |
Kõik kohustused | 60,08 mld | −19,30% |
Kogu omakapital | 43,44 mld | — |
Emiteeritud aktsiate arv | 2,00 mld | — |
Hinna ja väärtuse suhe P/B | 4,84 | — |
Varade tasuvus | 10,97% | — |
Kapitali tasuvus | 15,05% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | sept 2024info | Y/Y muutus |
---|---|---|
Puhastulu | 3,19 mld | 81,09% |
Põhitegevuse rahakäive | 6,29 mld | 16,88% |
Investeeringute raha | −374,00 mln | 83,09% |
Finantseerimise raha | −382,00 mln | 54,09% |
Raha ja raha ekvivalentide muutus | 5,71 mld | 275,39% |
Tasuta rahavoog | 4,55 mld | −63,57% |
Teave
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, “novae artes”.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Tegevjuht
Asutatud
29. veebr 1996
Peakontor
Veebisait
Töötajate arv
76 057